New antibody trial targets debilitating skin hardening in transplant patients
NCT ID NCT07011810
Summary
This study is testing a drug called axatilimab for people who develop thick, hard skin after a donor stem cell transplant, a condition called sclerotic chronic graft-versus-host disease (cGVHD). The drug is an antibody given by IV that aims to block cells involved in the scarring and inflammation process. Researchers want to see if it can improve skin hardening or stop it from getting worse in up to 50 adult participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact
-
Fred Hutch/University of Washington Cancer Consortium
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
Contact
Conditions
Explore the condition pages connected to this study.